Among older adults with classical Hodgkin lymphoma, frontline N-AVD has been found to be highly effective and well-tolerated.

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Takeda and Seattle Genetics are closing in on a new front-line use for their Adcetris in classical Hodgkin lymphoma after a successful late-stage trial. The positive results from the phase 3 ...

On World Cancer Day, Mamta Mohandas, Yuvraj Singh, Lisa Ray, and others inspire with their cancer survival stories.

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

A 60-year-old female patient presented with a rare case of coexisting diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma. This case report was published in Cureus, highlighting the ...

The mum-of-two claims it was only after repeat visits and tests over the ensuing months that she was finally diagnosed with stage four classical Hodgkin's lymphoma in October last year.

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...